1403-0008: A Phase II/III, randomized, open-label, multi-centre study of BI 907828 compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma
Oral MDM2 inhibitor BI 907828 vs doxorubicin
For the treatment of patients with an MDM2-mutant, TP53 wild type dedifferentiated liposarcoma that has not yet been treated in the advanced/metastatic setting.
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
Contact us today to request an appointment.Virtual & Telemedicine available.
Learn more news and information related to COVID-19.